Laboratorios Richmond SACIF (RICH) - Total Liabilities
Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) has total liabilities worth AR$282.24 Billion ARS (≈ $204.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Laboratorios Richmond SACIF (RICH) long-term investment share to see how much of total assets are deployed in long-term investments.
Laboratorios Richmond SACIF - Total Liabilities Trend (2006–2024)
This chart illustrates how Laboratorios Richmond SACIF's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see RICH total asset value.
Laboratorios Richmond SACIF Competitors by Total Liabilities
The table below lists competitors of Laboratorios Richmond SACIF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Manaksia Steels Limited
NSE:MANAKSTEEL
|
India | Rs2.67 Billion |
|
Viatron Technologies Inc
KQ:141000
|
Korea | ₩23.60 Billion |
|
Cps Technologies
NASDAQ:CPSH
|
USA | $4.78 Million |
|
Tamawood Ltd
AU:TWD
|
Australia | AU$19.87 Million |
|
Maxiparts Ltd
AU:MXI
|
Australia | AU$97.45 Million |
|
Renergen Ltd.
JSE:REN
|
South Africa | ZAC1.70 Billion |
|
Tycoons Group Enterprise Co Ltd
TW:2022
|
Taiwan | NT$4.50 Billion |
|
NICE Total Cash Management Co. Ltd
KQ:063570
|
Korea | ₩471.11 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Laboratorios Richmond SACIF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Laboratorios Richmond SACIF balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laboratorios Richmond SACIF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual total liabilities of Laboratorios Richmond SACIF from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AR$194.80 Billion ≈ $140.96 Million |
-32.20% |
| 2023-12-31 | AR$287.34 Billion ≈ $207.92 Million |
+842.02% |
| 2022-12-31 | AR$30.50 Billion ≈ $22.07 Million |
+50.13% |
| 2021-12-31 | AR$20.32 Billion ≈ $14.70 Million |
+327.48% |
| 2020-12-31 | AR$4.75 Billion ≈ $3.44 Million |
+56.62% |
| 2019-12-31 | AR$3.03 Billion ≈ $2.20 Million |
+90.35% |
| 2018-12-31 | AR$1.59 Billion ≈ $1.15 Million |
+84.39% |
| 2017-12-31 | AR$864.59 Million ≈ $625.62K |
+28.72% |
| 2016-12-31 | AR$671.67 Million ≈ $486.03K |
+53.80% |
| 2015-12-31 | AR$436.71 Million ≈ $316.01K |
+49.23% |
| 2014-12-31 | AR$292.64 Million ≈ $211.76K |
+49.05% |
| 2013-12-31 | AR$196.34 Million ≈ $142.07K |
+9.72% |
| 2012-12-31 | AR$178.94 Million ≈ $129.48K |
+64.29% |
| 2011-12-31 | AR$108.92 Million ≈ $78.82K |
+19.74% |
| 2010-12-31 | AR$90.96 Million ≈ $65.82K |
+22.74% |
| 2009-12-31 | AR$74.11 Million ≈ $53.62K |
+3.88% |
| 2008-12-31 | AR$71.34 Million ≈ $51.62K |
+10.89% |
| 2007-12-31 | AR$64.33 Million ≈ $46.55K |
+32.35% |
| 2006-12-31 | AR$48.61 Million ≈ $35.17K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more